Monte Rosa Therapeutics Inc (GLUE)vsModerna Inc (MRNA)
GLUE
Monte Rosa Therapeutics Inc
$10.27
-2.19%
HEALTHCARE · Cap: $1.07B
MRNA
Moderna Inc
$203.21
+6.95%
HEALTHCARE · Cap: $75.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 7656% more annual revenue ($2.23B vs $28.73M). GLUE leads profitability with a 0.0% profit margin vs -141.4%. GLUE earns a higher WallStSmart Score of 25/100 (F).
GLUE
Avoid25
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GLUE.
Margin of Safety
+69.9%
Fair Value
$134.59
Current Price
$203.21
$68.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -24.9% — below average capital efficiency
Trading at 12.0x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GLUE
The strongest argument for GLUE centers on Debt/Equity, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : GLUE
The primary concerns for GLUE are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GLUE profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
GLUE carries more volatility with a beta of 1.50 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
GLUE generates stronger free cash flow (-88M), providing more financial flexibility.
Bottom Line
GLUE scores higher overall (25/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Monte Rosa Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?